ライフサイエンスコーパス: immunomodulating

1 e impact of oxidation on the antioxidant and immunomodulating ability of FPH.

2 high-avidity neutralizing antibodies and (2) immunomodulating activities mostly including downregulat

3 organ of the human body and exerts profound immunomodulating activities.

4 xplain the outstanding anti-inflammatory and immunomodulating activity of JAK inhibitors currently us

5 gies could be used to deliver molecules with immunomodulating activity to the graft itself or to defi

6 suggesting that low-dose rituximab exerts an immunomodulating activity.

7 cyte coculture in the absence or presence of immunomodulating agent cyclosporine (3 or 30 ng/mL), dex

8 (1000 ng/mL); coculture with monocytes; the immunomodulating agent cyclosporine (Cys; 30 ng/mL); the

9 treated mice emphasized its usefulness as an immunomodulating agent for allergic fungal diseases.

10 tigated the effect of vesnarinone as a novel immunomodulating agent on CD4XL-induced T-cell apoptosis

11 lts indicate that cNK-2 is a potential novel immunomodulating agent rather than an antimicrobial agen

12 le-4-carboxamide-1-beta-D-ribofuranoside, an immunomodulating agent that activates AMP-activated prot

13 86 cases (66.3%) received a cytotoxic or an immunomodulating agent.

14 rom fungal cell walls have potential uses as immunomodulating agents and vaccine adjuvants.

15 Immunomodulating agents are a new class of drugs that ch

16 Immunomodulating agents dexamethasone (Dex), IL-10, and

17 have been shown to be the new generation of immunomodulating agents in transplantation tolerance ind

18 d considering the early use of a second-line immunomodulating agents or pulse intravenous methylpredn

19 g of Kupffer cells with liposomes containing immunomodulating agents such as butyrate may be a useful

20 ciation of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients with AID with

21 ns during cancer immunotherapy that involves immunomodulating agents, and the pressing need for novel

22 apy, anti-angiogenic compounds, vaccines and immunomodulating agents, differentiation agents, cytotox

23 treated with different immunosuppressive and immunomodulating agents, followed by 1 to 3 cycles of ri

24 ion of standard therapy with newly developed immunomodulating agents, such as antibodies blocking cyt

25 ongitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whet

26 venile and adult DM, even in the presence of immunomodulating agents.

27 lpha and IFN-gamma are cytokines with potent immunomodulating and anti-tumor activities.

28 Our findings provide a potentially novel immunomodulating approach against AA.

29 ibodies but the optimal roles of traditional immunomodulating as well as newer biologic therapies in

30 e of prime importance for the development of immunomodulating compounds.

31 58 is the first lead compound in a series of immunomodulating decapeptides discovered through activit

32 ying mutations affecting several potentially immunomodulating domains.

33 3-Val4-Tyr5) is known for its activity as an immunomodulating drug, but with limited half-life in pla

34 with refractory disease may respond to other immunomodulating drugs, including anti-TNF-alpha antibod

35 Opiates are known to exert a number of immunomodulating effects in vitro and in vivo, and we so

36 The current preclinical study expands the immunomodulating effects of enteral nutrition as previou

37 e adult (LADA) is safe and suggests possible immunomodulating effects of GAD65.

38 is the first study to compare the potential immunomodulating effects of these commonly used agents.

39 Thus, probiotics LGG+Bb12 exert divergent immunomodulating effects, with enhanced Th1 responses to

40 is thought to have some proinflammatory and immunomodulating effects.

41 therapy, and has demonstrated anti-tumor and immunomodulating effects.

42 of innate immune cells through TLR triggers immunomodulating events that enhance cell-mediated immun

43 er, SOM induces the production of the potent immunomodulating factor alpha-MSH by TCR-stimulated prim

44 COX-2, and (interleukin) IL-8 as well as the immunomodulating factors IL-6, transforming growth facto

45 e possibility that this viral protein has an immunomodulating function and may explain the mechanism

46 The use of immunomodulating gene therapy in the treatment of malign

47 e cassette of adenovirus early region 3 (E3) immunomodulating genes in pancreatic beta cells.

48 Therefore, inactivation of immunomodulating genes such as B13R or B22R represents a

49 B13R (SPI-2) and B22R (SPI-1) are two VV immunomodulating genes with sequence homology to serine

50 Furthermore, prolactin represents a novel immunomodulating hormone for the treatment of immunodepr

51 nicians must choose from among the available immunomodulating, immunosuppressive, and targeted immuno

52 Immunomodulating mAbs directed against immune cell targe

53 tion of TAA mRNA together with mRNA encoding immunomodulating molecules is a promising vaccination st

54 Further research into TLR7 immunomodulating pathways as a basis for effective immun

55 Two immunomodulating polysaccharides, poly-(1-6)-beta-glucot

56 Extracorporeal photopheresis (ECP), an immunomodulating procedure that treats pheresed blood wi

57 gram-negative bacteria demonstrate numerous immunomodulating properties and are involved in the viru

58 dominantly produced by the adult kidney, has immunomodulating properties that are required for sponta

59 unoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell

60 is a polyclonal IgG preparation with potent immunomodulating properties.

61 the time of bronchoscopy and analyzed for 28 immunomodulating proteins via multiplex bead array or en

62 Immunomodulating regulatory T-cell (Treg) therapy is a p

63 We studied the immunomodulating role of BECs in a human ex vivo model o

64 Our data indicates a possible immunomodulating role of LdTyrRS in Leishmania infection

65 Moreover, brain-centered glucoregulatory and immunomodulating systems that mediate peripheral health

66 This study explored the effect of the immunomodulating tellurium compound ammonium trichloro (

67 of erythroid bursts in culture responded to immunomodulating therapies (sensitivity 96%, specificity

68 nists may be a strategy for developing novel immunomodulating therapies against cancer.

69 trials of immunosuppression, antiviral, and immunomodulating therapies are needed.

70 idence-based treatment, but various systemic immunomodulating therapies are used.

71 yclosporine were the most promising systemic immunomodulating therapies for SJS/TEN.

72 -allergen conjugates, and anti-IL-5 as novel immunomodulating therapies in allergy.

73 However, the role of antifungal and immunomodulating therapies in patients with ABPA, ABPM,

74 New immunomodulating therapies may also have a role TED mana

75 ven in the absence of autoimmune diseases as immunomodulating therapies may be effective in shortenin

76 Overall, 28 patients responded to either immunomodulating therapies or drug withdrawal.

77 nonrandomized studies on therapies (systemic immunomodulating therapies or supportive care) for SJS/T

78 eripheral nerve and establish how a range of immunomodulating therapies, including current treatments

79 d therapies were supportive care or systemic immunomodulating therapies, including glucocorticosteroi

80 s), is unresponsive to immunosuppressive and immunomodulating therapies.

81 is some evidence that immunosuppressive and immunomodulating therapy are effective for chronic, viru

82 n tested in clinical trials without a single immunomodulating therapy showing consistent benefit.

83 ffective in patients who are unresponsive to immunomodulating therapy, such as interferon beta and gl

84 Despite immunomodulating therapy, the patient died of overwhelmi

85 vere atopic dermatitis (AD) require systemic immunomodulating treatment to achieve adequate disease c

86 controlled trials (RCTs) evaluating systemic immunomodulating treatments for moderate-to-severe AD we

87 To provide an overview on possible immunomodulating treatments for SJS/TEN and estimate the

88 comprehensive overview on proposed systemic immunomodulating treatments for SJS/TEN, which is of gre

89 , have shown partial response to a number of immunomodulating treatments, but the search for more eff

90 ence or absence of infection with a group of immunomodulating viruses, particularly cytomegalovirus.